A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282, Administered for 12 Weeks in Patients with Primary Sclerosing Cholangitis (PSC)
Administered By
Awarded By
Contributors
- Muir, Andrew Joseph Principal Investigator
Start/End
- November 1, 2015 - April 30, 2019